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G protein-coupled receptors (GPCRs) are essential cell membrane signaling
molecules and represent the most important class of drug targets. Some
signaling pathways downstream of a GPCR may be responsible for drug
adverse effects, while others mediate therapeutic efficacy. Biased ligands
preferentially activate only a subset of all GPCR signaling pathways. They
hold great potential to become next-generation GPCR drugs with less side
effects due to their potential to exclusively activate desired signaling path-
ways. However, the molecular basis of biased agonism is poorly under-
stood. GPCR activation occurs through allosteric coupling, the propagation
of conformational changes from the extracellular ligand-binding pocket to
the intracellular G protein-binding interface. Comparison of GPCR struc-
tures in complex with G proteins or b-arrestin reveals that intracellular
transducer coupling results in closure of the ligand-binding pocket trapping
the agonist inside its binding site. Allosteric coupling appears to be trans-
ducer-specific offering the possibility of harnessing this mechanism for the
design of biased ligands. Here, we review the biochemical, pharmacologi-
cal, structural, and biophysical evidence for allosteric coupling and delin-
eate that biased agonism should be a consequence of preferential allosteric
coupling from the ligand-binding pocket to one transducer-binding site. As
transducer binding leads to large structural rearrangements in the extracel-
lular ligand-binding pocket, we survey biased ligands with an extended
binding mode that interact with extracellular receptor domains. We pro-
pose that biased ligands use ligand-specific triggers inside the binding
pocket that are relayed through preferential allosteric coupling to a specific
transducer, eventually leading to biased signaling.
Introduction
G protein-coupled receptors (GPCRs), with more than
800 members, form the largest class of cell membrane
receptors and mediate the vast majority of physiologi-
cal functions in humans [1,2]. GPCRs can sense a myr-
iad of extracellular stimuli such as neurotransmitters,
hormones, lipids, peptides, proteins, nucleotides, ions,
photons, and odorants and relay this information into
cellular responses by activating intracellular heterotri-
meric G proteins. As the binding sites for extracellular
ligands and G proteins are on opposite sides of the cell
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membrane, GPCR activation follows a process called
allosteric coupling to relay information through the
receptor core. Extracellular ligand binding leads to
conformational changes in the receptor protein that
allosterically favors binding of G proteins at the intra-
cellular site of the receptor [3–5].
G protein activation subsequently triggers changes
in the intracellular concentration of second messengers
such as 3’,5’-cyclic adenosine monophosphate
(cAMP), calcium ions (Ca2+), diacylglycerol (DAG),
and inositol 1,4,5-trisphosphate (IP3), which activate
downstream target proteins, eventually leading to
specific cellular responses. To exert spatiotemporal
control over cell function, GPCR signaling is not lim-
ited to the cell membrane but can also emerge from
intracellular compartments such as early endosomes,
the trans-Golgi network, or the nucleus [6]. In addi-
tion, the concentration of second messengers at differ-
ent locations in the cell is not uniform and it has
been demonstrated that second messengers, especially
Ca2+ and cAMP, are compartmentalized in cells [7–
10], allowing GPCRs to fine-tune cell signaling with
high precision in space and time. Thus, by controlling
innumerable cellular processes in physiology and dis-
ease, GPCRs hold a pivotal role in cell signaling.
Based on this key function, GPCRs have emerged as
one of the most popular and most important drug
targets accounting for more than a third of currently
marketed drugs [11,12].
G proteins are organized in 4 different families (Gs,
Gi/o, Gq/11, and G12/13) and comprise a total of 16 dis-
tinct subfamilies based on their Ga subunits [13].
Although it was commonly believed that every GPCR
couples to a specific G protein subfamily, an over-
whelming amount of evidence has now unequivocally
shown that GPCRs are promiscuous signaling proteins
in such that they can activate G proteins from multiple
families. Upon activation, GPCRs are desensitized
through phosphorylation by G protein-coupled recep-
tor kinases (GRKs) and subsequent binding of b-ar-
restin, ultimately leading to receptor internalization
[14]. Besides its role in GPCR internalization, b-ar-
restin can act as a scaffold for further signaling pro-
teins such as kinases and phosphodiesterases among
others [15]. Moreover, in recent years it has been
appreciated that b-arrestin can bind to GPCRs in at
least two distinct conformations, a ‘tail’ conformation
favoring interactions with the phosphorylated C termi-
nus of the receptor and a ‘core’ conformation compris-
ing strong interactions with the receptor’s
transmembrane core [16–18]. To add further complex-
ity, the distinct GPCR–arrestin complexes appear to
exert distinct cellular functions [19–22].
Importantly, numerous GPCR ligands have been
described that are able to preferentially activate one
signaling pathway over others, for example, G protein
signaling over b-arrestin recruitment or, more subtly
nuanced, one G protein subfamily (e.g., Gas) over
another (e.g., Gai/o) [14,23–25]. These ligands are com-
monly referred to as biased ligands. From a therapeutic
point of view, this may be highly valuable as it has
been suggested that some signaling pathways down-
stream of a particular GPCR may mediate therapeuti-
cally desired effects while others may be responsible
for drug adverse effects. Due to their potential of pre-
senting drugs with no or fewer side effects, biased
ligands have emerged as a highly sought-after class of
future GPCR drugs [12,26]. However, the structural
basis of how biased ligand-mediated GPCR activation
results in preferential coupling to a subset of signaling
proteins at the expense of others is poorly understood.
Along this line, for most diseases the signaling path-
ways responsible for drug adverse effects are yet not
known. Therefore, it is currently extremely challenging
to design biased ligands for GPCRs [27], a fact that is
also mirrored by the very small number of marketed
biased ligands.
Here, we review the biochemical, structural, bio-
physical, and computational evidence of allosteric cou-
pling as the fundamental mechanism of GPCR
activation. Special attention will be given to how
biased ligands may selectively impact the allosteric
coupling mechanism and how this may eventually lead
to biased signaling.
Structural basis of GPCR activation
The last decade has witnessed a revolution in struc-
tural biology of GPCRs. To date, almost 500 struc-
tures have been solved including receptors in the apo
state, receptors bound to ligands of diverse pharmacol-
ogy (full agonists, partial agonists, antagonists, inverse
agonists, and allosteric modulators), and, most impor-
tantly, dozens of ternary complexes of receptor, ago-
nist, and G protein, the latter visualizing the essential
GPCR signaling unit at atomic resolution. From this
wealth of structural data, a common activation mecha-
nism of the GPCR superfamily has been deduced and
is covered in great detail by excellent recent reviews
[3–5]. In brief, agonist binding to the extracellular part
of the receptor stabilizes large-scale conformational
changes through the receptor’s transmembrane core
that ultimately lead to binding of a G protein at the
intracellular surface of the receptor. Importantly, the
binding sites for the agonist and the G protein do not
overlap, but are structurally linked via conformational
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coupling, which is defined as allosteric coupling. Ago-
nist binding leads to contraction of the ligand binding
pocket and to conformational changes of the (mostly)
conserved P5.50 – I3.40 – F6.44 motif at the bottom of
the binding pocket (numbering according to the Balles-
teros-Weinstein nomenclature). This results in confor-
mational changes in the conserved toggle-switch
epitope W6.48 causing a large outward swing of the
inner half of transmembrane domain 6 (TM6) (Fig. 1).
The intracellular outward movement of TM6 allows
binding of the C-terminal part of the Ga subunit.
Breaking of a salt-bride between D(E)3.49 and R3.50
upon receptor activation leads to rearrangement of the
conserved D(E)3.49 – R3.50 – Y3.51 motif stabilizing G
protein binding particularly through a direct interac-
tion of R3.50 with the G protein. Moreover, the active
G protein-coupled receptor state is stabilized by a
rearrangement of the conserved N7.49 – P7.50 – x – x–
Y7.53 motif (Fig. 1). In contrast to these conserved acti-
vation hot spots, much less is known about how biased
ligands may influence this process. This is mainly due
to the paucity of biased ligand-bound GPCR struc-
tures in complex with two different signal transducers.
Moreover, rather little is known about the dynamics
of how conformational changes are relayed from the
ligand-binding pocket to the intracellular G protein-
binding site in general.
Allosteric coupling
Activation of GPCRs upon agonist binding is a classi-
cal allosteric process in which conformational changes
in the extracellular ligand-binding pocket are allosteri-
cally linked to conformational changes in the intracel-
lular transducer (G protein or b-arrestin)-binding
interface. Already in 1976, Alfred G. Gilman and
Robert J. Lefkowitz independently published two semi-
nal papers in which they demonstrated that the affinity
of agonists to b-adrenergic receptors is highly sensitive
to the presence of guanine nucleotides [28,29]. Specifi-
cally, using equilibrium binding experiments where
b-adrenergic receptors were labeled with the radioactive
antagonists [125I]iodohydroxybenzylpindolol [28,30] or
[3H]dihydroalprenolol [29], it was shown that agonist-
binding curves were shifted significantly to the right in
the presence of high concentrations of GTP, GDP, or
guanyl-5’-yl imidodiphosphate, revealing a significant
decrease in agonist affinity. Most importantly, this
effect was exclusive to agonists as binding curves of
antagonists were unaffected by the presence of guanine
nucleotides. It was later shown that agonist competi-
tion binding curves are biphasic and characterized by
two fractions representing high and low affinities of the
agonist [31]. Addition of guanine nucleotides results in
monophasic agonist competition curves due to elimina-
tion of the high-affinity fraction. These data have
demonstrated that the high-affinity fraction of agonist
binding corresponds to a G protein-bound state of
receptors and, in fact, both the ratio of high to low
agonist affinity and the size of the high-affinity fraction
correlate well with agonist efficacy [31]. Most impor-
tantly, these biochemical studies have been formalized
in quantitative terms and led to the development of the
ternary complex model [32]. It describes conceptually
Fig. 1. Inactive and active GPCR crystal
structures unveil common conformational
changes upon receptor activation. The
upper row shows a superimposition of the
active (gold) and the inactive (dark gray)
muscarinic M2 receptor co-crystallized with
the agonist iperoxo (PDB entry: 4MQS) [48]
and QNB (PDB entry: 3UON) [47],
respectively. The row below shows a
superimposition of the active (green) and
the inactive (light gray) b1-adrenergic
receptor (PDB entries: 2Y03 and 2YCW,
respectively)[115,116]. While the largest
conformational change at the extracellular
side is depicted as an inward movement of
TM6, the reciprocal effect (large outward
movement of TM6) can be observed at the
intracellular side.
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and also quantitatively the allosteric coupling mecha-
nism of GPCR activation in biochemical terms: Ago-
nist binding favors G protein coupling and G protein
coupling to the receptor increases agonist, but not
antagonist, affinity. Based on the discovery of sponta-
neous activity of GPCRs, this model was later extended
[33]. After the initial biochemical description of allos-
teric coupling at b-adrenergic receptors, increased ago-
nist affinity in the presence of G proteins has been
demonstrated at muscarinic [34], opioid [35], adenosine
[36], and a-adrenergic receptors [37] and is now
believed to be a common hallmark of all GPCRs.
Of note, ternary complex formation is not limited to G
proteins. After the discovery of b-arrestin [38], it was
shown that b-arrestin binding to GPCRs does also
increase agonist affinity indicative of formation of an
agonist/receptor/b-arrestin ternary complex analogous to
the one observed with G proteins [39–42]. In quantitative
terms, b-arrestin coupling to GPCRs has been formalized
in the so-called alternative ternary complex model [39].
More recently, by comparing wild-type angiotensin
receptors with angiotensin receptors fused to either Gaq
or b-arrestin2, it has been demonstrated that competition
binding curves of biased ligands (either Gaq over b-ar-
restin2 or vice versa) at either fusion proteins were left-
shifted to a different extent in comparison with wild-type
receptors [43]. For instance, competition binding curves
of G protein-biased ligands (e.g., TRV055 and TRV056)
at AT1R-Gq receptors were much greater shifted to the
left in comparison with AT1R than competition curves at
AT1R-barr2 receptors. In contrast, competition binding
curves of barr2-biased ligands (e.g., TRV023 and
TRV026) were more prominently left-shifted at AT1R-
barr2 receptors [43]. These data led to the hypothesis that
the molecular nature of biased ligands may lie in prefer-
ential stabilization of G protein-stabilized ternary com-
plexes over barr2-stabilized ternary complexes or vice
versa, thereby establishing the first biochemical link
between divergent (i.e., transducer-specific) allosteric cou-
pling and biased agonism.
Collectively, the biochemical evidence of more than
40 years has unequivocally shown that GPCR activa-
tion is an allosteric process. Of note, there is initial
evidence that allosteric coupling may be dependent on
the type of ligand and the type of signaling protein,
suggesting that it may be possible to harness this pro-
cess with designed ligands to ultimately control prefer-
ential transducer coupling and biased signaling.
Structural basis of allosteric coupling
Despite the detailed biochemical understanding of
allosteric coupling, the structural basis of this
fundamental process has remained enigmatic until
recently. Using purified receptors (specifically b2-
adrenergic, muscarinic M2, and µ-opioid receptors)
and G proteins (or G protein mimetic nanobodies)
reconstituted in high-density lipoprotein particles, it
was revealed that binding of nucleotide-free G proteins
to receptors severely impairs both the association and
the dissociation of ligands to the extracellular binding
pocket in a concentration-dependent manner [44].
Mapping these pharmacological data on the available
crystal structures of the three receptors elucidated the
molecular mechanism of allosteric coupling: Binding
of a G protein to the intracellular receptor surface
leads to closure of the extracellular ligand-binding
pocket, virtually trapping the ligand in its binding site
and preventing further ligand access to the binding site
from the extracellular space [44]. In general, conforma-
tional changes in the extracellular loops 2 and 3 and
the extracellular parts of TM5, TM6, and TM7 of the
receptors appear to be responsible for forming a lid-
like structure over the ligand-binding pocket [3]
(Fig. 1). More specifically, in b-adrenergic [45,46] and
muscarinic receptors [47,48] two aromatic residues in
the ECL2 and upper part of TM7 move closer to one
another. It should be noted that in muscarinic
receptors, these aromatic residues form parts of the
common allosteric-binding site and that their rear-
rangement during receptor activation allows designing
allosteric modulators that favor binding to either the
inactive or active states of the receptor [49,50]. Closure
of the ligand-binding pocket hence provides the struc-
tural basis of the observed increase in agonist affinity
in the presence of G proteins and is likely to be a con-
ceptually common mechanism for allosteric coupling
during GPCR activation [44,51].
Although there is detailed knowledge about the
specific structural changes within both the ligand and
the transducer-binding sites, much less is known about
the structural dynamics of the conformational coupling
of these regions. In particular, it is largely unknown
how structural changes in the ligand-binding pocket
are precisely relayed through the receptor core to the
transducer-binding site and how this may be influenced
by different ligands and different transducers.
As crystallography only provides extreme snapshots
of GPCR activation, cryo-EM and other biophysical
techniques such as nuclear magnetic resonance (NMR)
spectroscopy, double electron–electron resonance
(DEER) spectroscopy, and single-molecule Foerster
resonance energy transfer (smFRET) have become
invaluable to shed light on structural dynamics of
allosteric coupling. As a representative example
of the power of such biophysical methods, NMR
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spectroscopy of multiple GPCRs equipped with differ-
ent labels (13C, 15N, or 19F) has uniformly demon-
strated that allosteric coupling between the ligand-
binding pocket and the G protein-binding site is loose
[52–54]. Two key aspects can be extracted from these
studies: First, agonist binding stabilizes an ensemble
of different receptor conformations which are in equi-
librium with each other and are able to interconvert,
and second, the fully active state of the receptor is
only reached upon addition of the G protein or a G
protein mimicking nanobody [52–61]. The latter
notion has also been confirmed by using DEER [52]
or single-molecule FRET techniques [62]. Overall, this
indicates that agonist binding alone sort of primes the
receptor for subsequent engagement with a variety of
intracellular transducers. However, the major struc-
tural changes observed at both the intracellular G pro-
tein-binding site and the extracellular closure of the
ligand-binding pocket inevitably require the engage-
ment of the G protein.
The residues that get labeled for NMR spectroscopy
experiments are often predetermined by the amino acid
sequence of the receptor under study (e.g., with 13C-
methionine, all methionine residues will be labeled)
and it is possible to assign specific conformational
changes to specific residues that are scattered all over
the receptor protein. Therefore, NMR spectroscopy
has the advantage to simultaneously sample structural
changes at multiple locations all over the receptor pro-
tein due to labeling at multiple sites. This allows
extracting much more dynamic information of the acti-
vation process of receptors. Most of the labeled resi-
dues in NMR spectroscopy are located in the vicinity
of some conserved activation hot spots (e.g., the PIF,
D(E)RY, or NPxxY motifs) so that NMR spec-
troscopy can provide direct evidence of the structural
dynamics of the allosteric networks connecting the
ligand-binding pocket and the intracellular transducer-
binding interface.
Moreover, NMR spectroscopy allows to straightfor-
wardly assess the impact of different ligands on allos-
teric coupling between the two opposite binding sites.
By comparing conformational dynamics of specific
residues in response to different ligands, it has been
demonstrated that different ligands stabilize distinct
receptor conformations [52–60]. Based on this, it is
also likely that the allosteric pathways that link con-
formational changes in the ligand-binding pocket to
the intracellular receptor site may be distinct and
ligand-dependent [57,59,63].
To better elucidate the nature of those allosteric
pathways, computational approaches have proven
powerful tools to study allosteric communication
pipelines upon receptor activation on a much larger
scale. In general, a whole set of different ligand–recep-
tor complexes in inactive and active states form the
basis of structural data for computational analyses
[64–67]. Diverse methods such as evolutionary trace
analysis [68–71], phylogenetic analysis [65,66], or
molecular dynamic simulations and subsequent analy-
sis of residues contacts or torsion angles [72–75] have
been applied to help elucidate the structural dynamics
of allosteric coupling. Overarchingly, computational
studies have discovered allosteric communication
pipelines or allosteric networks, that is, residue con-
tacts connecting the extracellular domains with the
intracellular domains of the receptor (Fig. 2). Through
concerted or subsequent motions of several connected
residues, conformational changes triggered by the
ligand can be relayed from the extracellular binding
pocket throughout the receptor core to the intracellu-
lar G protein-binding interface. It is crucial to note
that upon analysis of hundreds of receptor structures,
it has become evident that presumably all class A
GPCRs share a so-called common activation pathway
that is characterized by conformational changes in
conserved residues, motifs, and switches that ulti-
mately converge at the G protein-binding site
[64,65,67] (Fig. 2). However, the precise allosteric
pathway is different at different receptors which pro-
vides the molecular basis that allows the diverse super-
family of GPCRs to become activated by ligands of
exceptionally diverse chemical scaffolds while main-
taining the common ability to activate the much smal-
ler class of G proteins. Moreover, recent
computational analysis of receptor structures in com-
plex with biased ligands has suggested that allosteric
communication pipelines toward the intracellular G
protein or b-arrestin interfaces may be distinct high-
lighting the potential of harnessing specific allosteric
communication pipelines for biased ligand design [75].
In summary, structural, biophysical, and computa-
tional studies have revealed key aspects of the struc-
tural dynamics of allosteric coupling during GPCR
activation and have illustrated that the exact allosteric
communication pipelines toward transducer-binding
interfaces will likely be ligand-dependent.
How does allosteric coupling relate to
biased agonism?
Biased agonists are endowed with the ability to prefer-
entially couple to one transducer protein over another,
thereby promoting preferential signaling through a
limited subset of all possible pathways downstream of
a specific GPCR. On the structural level, this
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phenomenon is hardly understood, mostly due to the
lack of receptor structures of a biased ligand in com-
plex with two different transducer proteins (e.g., G
protein and b-arrestin, using the exact same receptor
construct for all structure determinations). Neverthe-
less, a plausible explanation for preferential signaling
pathway activation is that the ligand–receptor struc-
ture in complex with one transducer will be different
from the structure of a complex with another trans-
ducer. Differential transducer coupling should be rea-
sonable to assume because GPCR activation, as
outlined above, is a prime allosteric process that
should follow the hallmarks of allostery, that is,
reciprocity and probe dependence. The reciprocity of
allosteric coupling during GPCR activation has been
clearly demonstrated on multiple levels. In biochemical
terms, agonist binding stimulates G protein coupling,
and reciprocally, G protein binding increases agonist
affinity. In structural terms, agonist binding promotes
an intracellular outward movement of TM6 facilitating
G protein binding, and reciprocally, G protein cou-
pling leads to closure of the extracellular ligand bind-
ing pocket. However, much less is known about the
structural dynamics of probe dependency. Theoreti-
cally, it is legitimate to hypothesize that biased ago-
nists promote preferential transducer coupling by
preferential (i.e., more energetically favorable) forma-
tion or stabilization of one transducer-specific receptor
complex over another. Based on the allosteric ternary
complex model and by defining the transducer proteins
as allosteric probes, it should directly follow that
binding of one transducer (e.g., G protein) will exert a
different effect on ligand–receptor interactions than
binding of another transducer (e.g., b-arrestin) to the
same receptor. In other words, the cooperativity
between agonist and transducer in the receptor G pro-
tein complex should be different from their cooperativ-
ity in the b-arrestin complex.
An important question is how this diverging cooper-
ativity may be reflected in structural terms, that is,
how binding of different intracellular transducers
would affect the conformation of the ligand-binding
pocket. As outlined above, it has been elegantly shown
that G protein binding closes off the ligand-binding
pocket from the extracellular space. However, it has
remained enigmatic whether binding of one receptor to
G proteins from different families results in divergent
conformational changes (e.g., different degrees of clo-
sure) of the ligand-binding pocket. Further, it has been
unknown whether receptor coupling to b-arrestin leads
to distinct conformations of the ligand-binding pocket
different from the ones induced by G protein binding
to the same receptor.
Recently, initial structural evidence has been pro-
vided that sheds light on these questions. High-resolu-
tion structures of three different receptors have been
obtained each in complex with two different transduc-
ers: The neurotensin receptor 1 has been solved in
complex with a Gi protein and b-arrestin1 [76,77], the
b-adrenergic receptor has been solved in complex with
the Gs-protein mimetic nanobody Nb80 [78], a Gs pro-
tein [79], and b-arrestin1 [78], and structures of the
Fig. 2. A common allosteric network
connects the extracellular ligand-binding
pocket with the intracellular transducer-
binding site. As an example, the salmeterol-
bound crystal structure of the b2 adrenergic
receptor (PDB entry: 6MXT)[103] was used
to map contact residues of the extracellular
domains of the binding pocket (dark orange)
and the classical orthosteric-binding site
(light orange). The chemically encoded
ligand information can be transferred to the
intracellular side via a broad allosteric
network consisting of some highly
conserved structural motives (different
shades of green) and more receptor-specific
triggers (shown as gray spheres) [67].
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muscarinic M2 receptor have been obtained in complex
with Go and b-arrestin1 [80,81]. However, only for the
muscarinic M2 receptor and the b1-adrenergic receptor
structures in complex with two distinct transducers
have been solved bound to the same agonist: The iper-
oxo-bound M2 receptor has been solved in complex
with Go [80] and b-arrestin1 [81], and the structures of
formoterol-bound b1-adrenergic receptor in complex
with the Gs-protein mimetic nanobody Nb80 and b-ar-
restin1 have been obtained [78]. Although, in both
cases, the receptor constructs and the overall condi-
tions for structure determination (detergent micelles vs
phospholipid bilayers) are slightly different and
nanobodies have some limitations [82], the structures
provide invaluable insight into how the type of intra-
cellular signaling protein changes the conformation of
the extracellular ligand binding pocket. Interestingly,
comparing the G protein-bound and b-arrestin-bound
structures of the two receptors clearly reveals major
differences in the extracellular parts of the ligand-bind-
ing pockets (Fig. 3). While G-protein coupling to both
receptors already leads to a closure of the ligand-bind-
ing pocket, binding of b-arrestin appears to result in
further conformational changes in the extracellular
receptor domains. Specifically, in both receptors, there
is an even more pronounced closure of the ligand-
binding pocket mediated by further inward movements
of the extracellular parts of TM6 and TM7 concomi-
tantly leading to conformational changes in ECL3.
Moreover, conformational changes in the upper parts
of TM5, ECL1, and ECL2 contribute to the distinct
overall structure of the binding pocket in comparison
with the G protein (mimetic)-bound structures.
These studies provide direct evidence that allosteric
coupling between the ligand and transducer-binding
sites indeed depends on the type of transducer. How-
ever, it should be noted that the biochemical impact of
these structural differences in the ligand-binding
pocket has not yet been studied and it is not clear
whether coupling to b-arrestin results in more severely
restricted ligand access to the binding site. Neverthe-
less, the overall divergent conformations of the binding
pockets of the receptors when in complex with G pro-
tein or b-arrestin provide an opportunity to design
ligands that may take advantage of these divergent
structural changes in such that it leads to preferential
downstream signaling.
Biased agonists and allosteric
coupling
Comparison of the G protein and b-arrestin complexes
of M2R and b1-AR demonstrates structural changes in
the overall binding pocket, in particular major confor-
mational differences in the most extracellular parts of
the binding pocket including the extracellular loops.
Based on these structural data, we have surveyed the
literature for recently reported biased ligands that have
a so-called extended binding mode, that is, ligands with
a molecular structure that spans the entire ligand-bind-
ing pocket including the upper parts of transmembrane
helices and extracellular loops. Interestingly, there are
a number of such biased ligands for several GPCRs
for which it was reported that the molecular basis for
their observed bias i the ligands’ extensive contacts
with the extracellular parts of the binding pocket.
Fig. 3. Transducer-specific conformations of the extracellular ligandbinding pocket. Structures of two given ligand/receptor complexes
coupled to two different intracellular transducers allow extracting and comparing transducer-specific allosteric coupling. For both receptor
pairs, similar conformational changes occur when comparing differences between M2 receptors (PDB entries: 6U1N and 6OIK) [80,81] and
b1-adrenoceptors (PDB entries 6TKO and 6IBL) [78] both bound to a G protein (or nanobody) and b-arrestin. Interestingly, the major
conformational differences between the two structural overlays occur in the most extracellular parts of the ligand binding pocket.
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Dopamine receptors
The dopamine D2 receptor is a major mediator of
dopamine signaling in the central nervous system and
serves as an important drug target for antipsychotics,
drugs for Parkinson’s disease, and antiemetics. D2
receptors couple to Gai/o proteins but can also recruit
b-arrestin. The structure of an active D2 receptor/Gi
complex bound to bromocriptine [83], a drug for
Parkinson’s disease, has been solved and reveals a
bitopic binding mode of bromocriptine where parts of
the ligand form extensive contacts with residues of the
extracellular loops of the D2 receptor including I184
in ECL2 (Fig. 4). Interestingly, bromocriptine has
been shown to be a b-arrestin-biased agonist at D2
receptors [84]. In line with this, compound 2 [85], a
congener of the drug aripiprazole [86,87] and a b-
arrestin-biased agonist, interacts extensively with the
extracellular domain including I184 as well (Fig. 4).
The idea is that by strong ligand interactions with
ECL2, compound 2 preferentially couples to b-arrestin
[85]. Moreover, compound 2 shows less interactions
with S1935.42 at the bottom of the binding pocket
which is an important trigger of Gai-protein coupling.
MLS1547 is a Gi/o-biased ligand [88,89] and shows
also strong interactions with a hydrophobic pocket in
the extracellular domains comprising I184 and
F1895.38 at the extracellular part of TM5. In contrast
to the two b-arrestin-biased ligands, the interaction of
MLS1547 with F1895.38 has been suggested to be
responsible for impaired b-arrestin recruitment. Taken
together, three biased ligands of diverse chemical scaf-
folds share a uniform mechanism of preferential allos-
teric coupling. Through strong interactions with
Fig. 4. Extended binding modes of biased ligands as structural hallmark for biased signaling. The examples for biogenic amine receptors
include the dopamine D2 receptor co-crystallized with the b-arrestin-biased drug bromocriptine (PDB entry: 6VMS)[83] or with a docked b-
arrestin-biased compound 2 (according to [85]), the 5-HT2B receptor co-crystallized with the b-arrestin-biased ergotamine (PDB entry: 4IB4)
[90], the muscarinic M2 receptor with the docked Gai-biased bitopic agonist iper-6-naph [51,113], and the b2 adrenergic receptor co-
crystallized with the Gas-protein-biased asthma therapeutic salmeterol (PDB entry: 6VMS)[103]. The blue and the gray surfaces indicate the
classical orthosteric and extended molecule parts, respectively. Receptor-ligand contacts with extracellular domains of the binding pocket
are highlighted in orange. A complementary way to interfere with allosteric coupling can be observed in the AT1 receptor co-crystallized with
the b-arrestin-biased peptide TRV026 (PDB entry: 6OS2)[98].
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residues in the extracellular parts of the ligand-binding
pocket, all three ligands trigger a distinct allosteric
pathway from the extracellular domain preferentially
leading to binding of only one transducer. In fact, for
MLS1547 it has been shown that the interaction with
F1895.38 favors a distinct conformation of ICL2 that
impairs b-arrestin coupling [89]. Thus, interaction with
extracellular residues appears as trigger for biased sig-
naling.
Serotonin receptors
Serotonin modulates a variety of physiological func-
tions in humans, for example, in the cardiovascular
system, the gastrointestinal tract, and the central ner-
vous system. Serotonin receptor antagonists are
important drugs in the treatment of nausea, migraine
and other diseases. Moreover, serotonin receptors in
the brain mediate hallucinogenic effects of psychedelic
drugs such as LSD. LSD and ergotamine are two
serotonin receptor agonists that have been crystallized
in complex with the 5-HT2B receptor [90–92]. The 5-
HT2B receptor couples preferentially to Gaq/11 pro-
teins bun can also recruit b-arrestin. Interestingly,
ergotamine and LSD are both b-arrestin-biased
ligands. The structures reveal an extended binding
mode for both ligands and, in particular ergotamine,
show direct interactions with extracellular parts of
TM6 (L3476.58, V3486.59), TM7 (Q3597.32), and ECL2
(L209) (Fig. 4). It has been suggested that the
enhanced interactions of the ligands with the extracel-
lular parts of the binding pocket are responsible for
the observed b-arrestin bias.
Angiotensin receptors
AT1 receptors mediate the majority of physiological
functions of angiotensin in humans such as vasocon-
striction. AT1 receptor antagonists (e.g., losartan)
serve as well-established drugs for the treatment of
hypertension and heart failure. In recent years, there
has been a lot of interest in b-arrestin-biased AT1
receptor agonists as potential drugs for heart failure
because studies have shown their antihypertensive
effects to be comparable with angiotensin antagonists
while b-arrestin recruitment appears to improve car-
diac function [93,94]. Very recently, b-arrestin-biased
AT1 agonists have been discussed as potential drugs
for COVID-19 [95]. Besides their therapeutic impor-
tance, AT1 receptors are paradigmatic for studying the
molecular nature of biased agonism. Numerous Gaq/11
(e.g., TRV055 and TRV056) and b-arrestin-biased ago-
nists (e.g., TRV023 TRV026) have been reported [43]
and the structural basis and dynamics of their biased
agonism have been elucidated recently [96–99]. A key
structural element of all biased angiotensin analogues
is the nature of the amino acid at position 8 which
binds deep in the orthosteric pocket (a phenylalanine
in angiotensin II, the endogenous agonist). Gaq/11-bi-
ased agonists have a bulky amino acid at position 8
(e.g., TRV055 and TRV056) whereas b-arrestin-biased
agonist contain a small amino acid (e.g., alanine in
TRV026) or lack the eighth amino acid entirely (e.g.,
TRV023). Crystal structures and biophysical experi-
ments have revealed that a bulky amino acid in posi-
tion 8 of the angiotensin peptide is necessary to
promote a rotamer shift of L1123.36 at the bottom of
the binding pocket that triggers a stronger outward
swing of the lower parts of TM6 resulting in strong
Gq/11 coupling (Fig. 4). In contrast, the lack of a bulky
amino acid in position 8 impairs the outward move-
ment of TM6 which forms the structural basis for b-
arrestin-biased agonism at AT1 receptors (Fig. 4). Of
note, although angiotensin peptides are large molecules
that span the entire ligand-binding pocket including
extracellular receptor domains, the observed biased
agonism in either direction (Gq/11 or b-arrestin)
appears to stem entirely from different ligand interac-
tions with residues at the bottom of the ligand-binding
pocket such as L1123.36. This interaction influences the
conformation of W2536.48 which is an important resi-
due within the allosteric network coupling the ligand-
binding pocket to the intracellular Gaq/11 protein-bind-
ing site (Fig. 4). Thus, bulky amino acids at position 8
in angiotensin peptides promote preferential allosteric
coupling to the Gaq/11 protein-binding interface.
b-adrenergic receptors
b1- and b2-adrenergic receptors mediate essential phys-
iological functions of the autonomic nervous system
such as controlling heart rate and respiration. b1-AR
blockers form a fundamental class of drugs in the
treatment of a variety of cardiovascular diseases, and
b2-AR agonists are pivotal in the treatment of bron-
chial asthma and chronic obstructive pulmonary dis-
ease. Both receptors have recently been crystallized
with biased agonists which provides insights into the
structural basis of biased signaling. The structures of
the b1-adrenergic receptor in complex with Nb80 (a
Gas-protein mimetic) and b-arrestin both bound to
formoterol, a b-arrestin-biased agonist [100], have been
solved [78]. Formoterol displays an extended binding
mode showing interactions with receptor residues of
the upper parts of TM6 and ECL2 (Fig. 3). Compar-
ison of the two structures has revealed that the b-
2521The FEBS Journal 288 (2021) 2513–2528 ª 2021 The Authors. The FEBS Journal published by John Wiley & Sons Ltd on behalf of
Federation of European Biochemical Societies.
A. Bock and M. Bermudez Allosteric coupling and biased agonism in GPCRs
arrestin bias of formoterol may be due to differences
at two interaction hot spots. There are less interactions
of formoterol with the receptor in the deep orthosteric
binding pocket which may impair a strong outward
swing of the lower parts of TM6 and, thus, impair
Gas-protein coupling. In stark contrast, formoterol
displays much more interactions with residues in the
extracellular parts of the binding pocket such as the
upper parts of TM6 (Fig. 3). Of note, ligand interac-
tions with extracellular residues have also been
observed in the b1-AR crystal structures bound to the
b-arrestin-biased agonists bucindolol and carvedilol
[101].
The b2-adrenergic receptor has been crystallized with
the Gas-biased partial agonist salmeterol [102,103], a
well-known drug for the treatment of bronchial
asthma. Salmeterol shows an extended binding mode
comprising strong interactions with extracellular
domains of the receptor (Fig. 4). Although salme-
terol’s bias relative to epinephrine has been suggested
to result from a different hydrogen-bond network
involving Ser2045.43 and Asn2936.55 deep in the orthos-
teric binding pocket, it shall be noted that salmeterol
appears more b-arrestin biased than salbutamol (which
is much smaller in size) [103], a pharmacological obser-
vation that may be due to salmeterol’s interaction with
extracellular receptor domains. Along this line, it has
been shown that (R,R0)-fenoterol preferentially acti-
vates Gas-protein over Gai/o-protein signaling at b2-
adrenergic receptors. Interestingly, this biased agonism
has been attributed to (R,R0)-fenoterol’s interaction
with Tyr3087.35, a conserved residue in the extracellu-
lar part of the ligand-binding pocket [104].
Muscarinic acetylcholine receptors
Muscarinic receptors play a crucial function in the
autonomous nervous system by mediating all parasym-
pathetic effects such as controlling cardiac function,
secretion of glands, and several processes in the central
nervous system involved in memory and learning [49].
In line with this, muscarinic receptors serve as important
drug targets for the treatment of a variety of diseases
including Alzheimer’s disease and chronic obstructive
pulmonary disease. Besides their pivotal role in physiol-
ogy and disease, muscarinic receptors are the paradig-
matic receptors for allosteric modulation [105]. All 5
receptor subtypes possess a so-called common allosteric-
binding site located on top of the orthosteric-binding
pocket for acetylcholine. This site can be targeted with a
huge variety of small molecules and peptides [48,106].
Bitopic ligands, that is, ligands that bind to the orthos-
teric and allosteric-binding site simultaneously, have
first been described for muscarinic receptors and have
been shown to have an extended binding mode [107–
112]. This is similar to the binding mode of biased
ligands at dopamine, serotonin, and b-adrenergic recep-
tors (Fig. 4). In fact, bitopic ligands at muscarinic M2
receptors have been shown to be Gai/o-biased agonists
and fail to recruit b-arrestin [109,113]. Iper-6-naph, a
well-characterized bitopic ligand, spans the entire
ligand-binding pocket including residue contacts with
extracellular receptor domains (Fig. 4). We have sug-
gested that, due to its extended binding mode, iper-6-
naph hampers the closure of the ligand-binding pocket
[51,109,113]. While this is a structural hallmark during
allosteric coupling, iper-6-naph binding to M2 receptors
appears to affect receptor coupling to b-arrestin more
severely than Gai/o-protein coupling, providing a struc-
tural explanation for the observed biased agonism.
Indeed, the recent cryo-EM structure of the M2R/b-ar-
restin complex [81] shows an even more contracted bind-
ing pocket (Fig. 3) rationalizing why bitopic ligands fail
to recruit b-arrestin at this receptor [109].
Recently, we have applied a similar strategy to mus-
carinic M1 receptors [114]. Using a set of bitopic ago-
nists, it was shown that progressive interference with
binding pocket closure reduces the number of G pro-
tein subfamilies that can couple to the receptor. This is
in line with the notion that ligand interactions with
extracellular receptor domains may promote preferen-
tial allosteric coupling to selected transducers.
Conclusion
Allosteric coupling is the fundamental mechanism of
GPCR activation and describes how these membrane
receptors relay structural changes upon extracellular
agonist binding through the transmembrane core to
intracellular coupling of a variety of transducers such
as G proteins and b-arrestin. Although this mecha-
nism has been studied with biochemical and pharma-
cological methods for decades, only recently the
structural basis for allosteric coupling has been eluci-
dated. Binding of intracellular transducer proteins to
GPCRs is conformationally coupled to pronounced
structural changes in the extracellular domains of the
ligand-binding pocket, resulting in closure of the bind-
ing pocket toward the extracellular space. The recip-
rocal structural changes in the binding pocket appear
to be transducer-specific, suggesting that it may be
possible to design biased ligand with desired signaling
profiles. It should be noted that the most dramatic
structural changes occur in the extracellular parts of
the binding pocket such as the upper parts of trans-
membrane helices and extracellular loops. Therefore,
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ligands with extended binding modes that span the
entire binding pocket are likely to be promising can-
didates for biased signaling. In fact, several biased
ligands with extended binding modes have been
described for a variety of receptors. For many of
these ligands, it has been demonstrated that their bias
results from ligand interactions with the extracellular
domains of the receptor. For others, distinct ligand–
receptor interactions deep inside the orthosteric bind-
ing site are more likely to be responsible for the
observed ligand bias. A mixture of both mechanisms
is also likely to occur. However, despite the varying
molecular flavors of ligand bias, we propose that it is
likely that all biased ligands described above share a
conceptually common mechanism of biased agonism.
Based on the available data, we hypothesize that
biased ligands use ligand-specific triggers within the
binding pocket that initiate a preferential allosteric
pathway to only one intracellular transducer-binding
site. For some receptors, these molecular triggers may
be located in the extracellular parts of the ligand-
binding pocket (e.g., for biogenic amine receptors),
whereas for other receptors, these triggers reside at
the bottom of the ligand-binding pocket (e.g., for
angiotensin receptors). Nevertheless, the initiation of
preferential allosteric coupling with one transducer-
binding site appears to be a common hallmark of all
biased ligands at class A GPCRs. A deeper structural
and pharmacological understanding of allosteric net-
works will likely boost the rational design of biased
ligands as a new generation of GPCR drugs.
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